{"id":69437,"date":"2026-07-06T14:49:38","date_gmt":"2026-07-06T06:49:38","guid":{"rendered":"https:\/\/flcube.com\/?p=69437"},"modified":"2026-07-06T14:49:40","modified_gmt":"2026-07-06T06:49:40","slug":"pyrotech-therapeutics-secures-hundreds-of-millions-in-pre-b-financing-to-advance-pyroptosis-targeted-immunomodulator-platforms-for-cancer-and-inflammatory-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69437","title":{"rendered":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Pyrotech (Beijing) Biotechnology Co., Ltd.<\/strong> (&#8220;<strong>Pyrotech Therapeutics<\/strong>&#8220;) announced the completion of its <strong>Pre-B financing round<\/strong>, raising <strong>hundreds of millions of RMB<\/strong> led by <strong>Shanghai STVC Leading Fund<\/strong> with participation from <strong>Beijing ZGC Science City Fund<\/strong> and <strong>Shanghai Minhang Financial Investment Development Co., Ltd.<\/strong> The capital injection will accelerate development of the company&#8217;s dual-platform approach targeting <strong>pyroptosis<\/strong>\u2014a novel form of programmed cell death\u2014with applications spanning <strong>cancer immunotherapy<\/strong> and <strong>inflammatory disease treatment<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-financing-structure-amp-strategic-allocation\" class=\"wp-block-heading\">Financing Structure &amp; Strategic Allocation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Investor<\/th><th>Role<\/th><th>Strategic Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>Shanghai STVC Leading Fund<\/strong><\/td><td>Lead Investor<\/td><td>Shanghai-based biological regulation platform development<\/td><\/tr><tr><td><strong>Beijing ZGC Science City Fund<\/strong><\/td><td>Participating Investor<\/td><td>Beijing small-molecule immunomodulator clinical advancement<\/td><\/tr><tr><td><strong>Shanghai Minhang Financial Investment<\/strong><\/td><td>Participating Investor<\/td><td>Cross-regional R&amp;D pipeline expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-fund-allocation-strategy\" class=\"wp-block-heading\">Fund Allocation Strategy<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Shanghai Subsidiary:<\/strong> Development of pyroptosis-targeted biological regulation novel drug R&amp;D technology platform<\/li>\n\n\n\n<li><strong>Beijing Operations:<\/strong> Clinical trials advancement for multiple small-molecule immunomodulator projects<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> Acceleration of preclinical projects and R&amp;D pipeline diversification<\/li>\n\n\n\n<li><strong>Regional Synergy:<\/strong> Leveraging Beijing-Shanghai resource advantages for sustainable healthcare innovation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-scientific-platform-pyroptosis-amp-innate-immunity-leadership\" class=\"wp-block-heading\">Scientific Platform: Pyroptosis &amp; Innate Immunity Leadership<\/h2>\n\n\n\n<h3 id=\"h-core-technology-differentiation\" class=\"wp-block-heading\">Core Technology Differentiation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>World-Leading Position:<\/strong> Recognized as global leader in innate immunity and pyroptosis research<\/li>\n\n\n\n<li><strong>Dual Therapeutic Approach:<\/strong><\/li>\n\n\n\n<li><strong>Immunomodulation:<\/strong> Small molecules and biomolecules targeting novel inflammasome\/pyroptosis checkpoints to regulate inflammatory response levels<\/li>\n\n\n\n<li><strong>Cancer Immunotherapy:<\/strong> Inducing pyroptosis in tumor cells to recruit and activate immune cells for enhanced tumor recognition and destruction<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-target-disease-areas\" class=\"wp-block-heading\">Target Disease Areas<\/h3>\n\n\n\n<h4 id=\"h-overactivated-immunity-disorders\" class=\"wp-block-heading\">Overactivated Immunity Disorders<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Neurodegenerative diseases<\/strong> (Alzheimer&#8217;s, Parkinson&#8217;s, ALS)<\/li>\n\n\n\n<li><strong>Inflammatory bowel disease (IBD)<\/strong> (Crohn&#8217;s disease, ulcerative colitis)<\/li>\n\n\n\n<li><strong>Sepsis<\/strong> and systemic inflammatory conditions<\/li>\n<\/ul>\n\n\n\n<h4 id=\"h-oncology-applications\" class=\"wp-block-heading\">Oncology Applications<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Low-response cancer immunotherapy enhancement<\/strong><\/li>\n\n\n\n<li><strong>Tumor microenvironment reprogramming<\/strong><\/li>\n\n\n\n<li><strong>Immune cell recruitment and activation<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immunotherapy Market Gap:<\/strong> Current checkpoint inhibitors achieve response rates of only 15-30% in most solid tumors, creating substantial opportunity for pyroptosis-based combination approaches<\/li>\n\n\n\n<li><strong>Inflammatory Disease Burden:<\/strong> Global IBD market alone projected to reach $25 billion by 2030, with neurodegenerative disease markets exceeding $10 billion annually<\/li>\n\n\n\n<li><strong>First-Mover Advantage:<\/strong> Pyroptosis represents an emerging therapeutic target with limited competitive landscape compared to established immune checkpoints<\/li>\n\n\n\n<li><strong>Platform Scalability:<\/strong> Dual small-molecule\/biomolecule approach enables rapid pipeline expansion across multiple indications<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications-amp-development-timeline\" class=\"wp-block-heading\">Strategic Implications &amp; Development Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Geographic Optimization:<\/strong> Beijing focus on small-molecule chemistry and clinical development; Shanghai emphasis on biologics and complex biological platforms<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Potential for breakthrough therapy designations given novel mechanism of action and high unmet medical need<\/li>\n\n\n\n<li><strong>Partnership Potential:<\/strong> Strong foundation for pharma collaborations in both oncology and inflammatory disease spaces<\/li>\n\n\n\n<li><strong>Clinical Milestones:<\/strong> Multiple IND-enabling studies expected to transition to clinical trials within 12-18 months<\/li>\n\n\n\n<li><strong>Manufacturing Strategy:<\/strong> Dual-platform approach requires investment in both traditional small-molecule GMP and advanced biologics manufacturing capabilities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The Pre-B financing positions Pyrotech Therapeutics to capitalize on its scientific leadership in pyroptosis biology while addressing two of the most significant challenges in modern medicine: enhancing cancer immunotherapy response rates and treating chronic inflammatory conditions with precision immunomodulation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pyrotech (Beijing) Biotechnology Co., Ltd. (&#8220;Pyrotech Therapeutics&#8220;) announced the completion of its Pre-B financing round,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69438,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[20,1892],"class_list":["post-69437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-pyrotech-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pyrotech (Beijing) Biotechnology Co., Ltd. (&quot;Pyrotech Therapeutics&quot;) announced the completion of its Pre-B financing round, raising hundreds of millions of RMB led by Shanghai STVC Leading Fund with participation from Beijing ZGC Science City Fund and Shanghai Minhang Financial Investment Development Co., Ltd. The capital injection will accelerate development of the company&#039;s dual-platform approach targeting pyroptosis\u2014a novel form of programmed cell death\u2014with applications spanning cancer immunotherapy and inflammatory disease treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69437\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases\" \/>\n<meta property=\"og:description\" content=\"Pyrotech (Beijing) Biotechnology Co., Ltd. (&quot;Pyrotech Therapeutics&quot;) announced the completion of its Pre-B financing round, raising hundreds of millions of RMB led by Shanghai STVC Leading Fund with participation from Beijing ZGC Science City Fund and Shanghai Minhang Financial Investment Development Co., Ltd. The capital injection will accelerate development of the company&#039;s dual-platform approach targeting pyroptosis\u2014a novel form of programmed cell death\u2014with applications spanning cancer immunotherapy and inflammatory disease treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69437\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T06:49:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-06T06:49:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases\",\"datePublished\":\"2026-07-06T06:49:38+00:00\",\"dateModified\":\"2026-07-06T06:49:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437\"},\"wordCount\":489,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0603.webp\",\"keywords\":[\"Finance\",\"Pyrotech Biotechnology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69437#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69437\",\"name\":\"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0603.webp\",\"datePublished\":\"2026-07-06T06:49:38+00:00\",\"dateModified\":\"2026-07-06T06:49:40+00:00\",\"description\":\"Pyrotech (Beijing) Biotechnology Co., Ltd. (\\\"Pyrotech Therapeutics\\\") announced the completion of its Pre-B financing round, raising hundreds of millions of RMB led by Shanghai STVC Leading Fund with participation from Beijing ZGC Science City Fund and Shanghai Minhang Financial Investment Development Co., Ltd. The capital injection will accelerate development of the company's dual-platform approach targeting pyroptosis\u2014a novel form of programmed cell death\u2014with applications spanning cancer immunotherapy and inflammatory disease treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69437\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/0603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69437#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"Pyrotech (Beijing) Biotechnology Co., Ltd. (\"Pyrotech Therapeutics\") announced the completion of its Pre-B financing round, raising hundreds of millions of RMB led by Shanghai STVC Leading Fund with participation from Beijing ZGC Science City Fund and Shanghai Minhang Financial Investment Development Co., Ltd. The capital injection will accelerate development of the company's dual-platform approach targeting pyroptosis\u2014a novel form of programmed cell death\u2014with applications spanning cancer immunotherapy and inflammatory disease treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69437","og_locale":"en_US","og_type":"article","og_title":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases","og_description":"Pyrotech (Beijing) Biotechnology Co., Ltd. (\"Pyrotech Therapeutics\") announced the completion of its Pre-B financing round, raising hundreds of millions of RMB led by Shanghai STVC Leading Fund with participation from Beijing ZGC Science City Fund and Shanghai Minhang Financial Investment Development Co., Ltd. The capital injection will accelerate development of the company's dual-platform approach targeting pyroptosis\u2014a novel form of programmed cell death\u2014with applications spanning cancer immunotherapy and inflammatory disease treatment.","og_url":"https:\/\/flcube.com\/?p=69437","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-06T06:49:38+00:00","article_modified_time":"2026-07-06T06:49:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69437#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69437"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases","datePublished":"2026-07-06T06:49:38+00:00","dateModified":"2026-07-06T06:49:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69437"},"wordCount":489,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69437#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp","keywords":["Finance","Pyrotech Biotechnology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69437#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69437","url":"https:\/\/flcube.com\/?p=69437","name":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69437#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69437#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp","datePublished":"2026-07-06T06:49:38+00:00","dateModified":"2026-07-06T06:49:40+00:00","description":"Pyrotech (Beijing) Biotechnology Co., Ltd. (\"Pyrotech Therapeutics\") announced the completion of its Pre-B financing round, raising hundreds of millions of RMB led by Shanghai STVC Leading Fund with participation from Beijing ZGC Science City Fund and Shanghai Minhang Financial Investment Development Co., Ltd. The capital injection will accelerate development of the company's dual-platform approach targeting pyroptosis\u2014a novel form of programmed cell death\u2014with applications spanning cancer immunotherapy and inflammatory disease treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69437#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69437"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69437#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp","width":1080,"height":608,"caption":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69437#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pyrotech Therapeutics Secures Hundreds of Millions in Pre-B Financing to Advance Pyroptosis-Targeted Immunomodulator Platforms for Cancer and Inflammatory Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/0603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69437"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69437\/revisions"}],"predecessor-version":[{"id":69439,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69437\/revisions\/69439"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69438"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}